– PRODUODOPA (foslevodopa/foscarbidopa) is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment…
PHARMA & CLINICAL TRIALS
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care…
Pfizer has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental…
The University of Rochester will house a new national center focused on using tissue-on-chip technology to develop…
Merck and Harpoon Therapeutics today announced that the companies have entered into a definitive agreement…
An average of 22 adolescents 14 to 18 years of age died in the U.S.…
Long-acting combination HIV regimens have the potential to transform the future of coordinated HIV clinical…
The world’s largest review on opioid medicines for cancer pain has found it is unclear…
